Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Opin Biol Ther. 2006 Jul;6(7):717-26.

Application of encapsulated cell technology for retinal degenerative diseases.

Author information

1
Neurotech USA, Inc., 6 Blackstone Valley Place, Suite 500, Lincoln, RI 02865, USA. w.tao@neurotechusa.com

Abstract

Ophthalmic disorders represent a rapidly growing disease area that is associated with the ageing population. Their sight is threatened by age-related macular degeneration, diabetic retinopathy, glaucoma and/or retinitis pigmentosa (RP). Few effective treatments for these disorders are available at present, in part due to lack of effective delivery of therapeutic molecules to the retina. Encapsulated cell technology (ECT) allows the controlled, continuous and long-term administration of protein drugs in the eye, where therapeutic agents are needed, and does not subject the host to the systemic exposure. Furthermore, the implants can be retrieved, providing an added level of safety. Ciliary neurotrophic factor (CNTF) has been shown to protect the retina from degeneration in 13 animal models, and ECT-based delivery of CNTF protected photoreceptors in the rcd1 dog model of RP.

PMID:
16805711
DOI:
10.1517/14712598.6.7.717
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center